Allopurinol
Back to searchMolecule Structure
Scientific Name
Allopurinol
Description of the Drug
Allopurinol is a xanthine oxidase inhibitor used to reduce urinary and serum uric acid concentrations in patients with gout, recurrent calcium oxalate calculi, and various malignancies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00437
http://www.drugbank.ca/drugs/DB00437
Brand Name(s)
Allopurinol, Aloral, Aluline 100, Aluline 300, Caplenal, Cosuric, Hamarin 100, Hamarin 300, Ledopur, Lopurin, Uricto, Xanthomax-100, Xanthomax-300, Zyloprim, Zyloric, Zyloric-300
Company Owner(s)
Sun Pharmaceutical Industries Inc, Watson Laboratories Inc, Abbott Laboratories Pharmaceutical Products Div, Chartwell Life Molecules Llc, Mylan Pharmaceuticals Inc, Purepac Pharmaceutical Co, Zydus Pharmaceuticals Usa Inc, Harman Finochem Ltd, Indoco Remedies Ltd, Casper Pharma Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Xanthine dehydrogenase | SINGLE PROTEIN | INHIBITOR | CHEMBL1929 |
Clinical Trial(s)
Unichem Links
| Atlas | allopurinol | ||||
| SureChEMBL | SCHEMBL4627 | ||||
| PharmGKB | PA448320 | ||||
| Human Metabolome Database | HMDB0014581 | ||||
| DrugBank | DB00437 | ||||
| PubChem: Thomson Pharma | 15146664 | 15119988 | |||
| PubChem | 135401907 | ||||
| Mcule | MCULE-5186178136 | ||||
| NMRShiftDB | 20025947 | ||||
| LINCS | LSM-5919 | ||||
| Nikkaji | J2.034F | ||||
| BindingDB | 35440 | 50140241 | 181133 | ||
| EPA CompTox Dashboard | DTXSID4022573 | ||||
| DrugCentral | 124 | ||||
| Brenda | 154362 | 194408 | 4335 | 153379 | 801 |
| ChemicalBook | CB1181254 | CB31081805 | CB3587524 | ||
| Guide to Pharmacology | 6795 | ||||
| rxnorm | ZYLOPRIM | ALLOPURINOL SODIUM | ALLOPURINOL | ALOPRIM | |
| PubChem: Drugs of the Future | 22395219 | ||||
| ChEBI | 40279 | ||||
| ZINC | ZINC000013298313 |
